Latest news for Thesis Gold (OTC:THSGF) Stock

Thesis Gold Inc is a junior resource company. The principal business of the Company is the identification, acquisition, exploration and evaluation of mineral properties.

News

Penny Stocks

Commodities

Markets

Trading Ideas

THSGF

Analyst Says Gold Co. Offering Superior Returns on the Path to Production

Thesis Gold Inc

CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) on Tuesday released an unaudited Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/pressreleases/24/07/n39595056/cleanspark-releases-june-2024-bitcoin-mining-update">mining and operations update</a>.
What Happened: CleanSpark announced it mined 445 bitcoin in June, bringing its total bitcoin mined year-to-date up to 3,614. The company said it was holding 6,591 bitcoin as of June 30 after selling 8.06 bitcoin last month at an average price of $67,514.
CleanSpark&#8217;s average hashrate through the month of June was 17.85 EH/s, resulting in an average of 14.83 bitcoin mined daily. CleanSpark noted that it exceeded its mid-year hash rate target of 20 EH/s as a result of its&nbsp;previously announced&nbsp;acquisition of five new&nbsp;bitcoin&nbsp;mining sites in&nbsp;Georgia.&nbsp;
&#8220;We reached a tremendous milestone on our path to 50 EH/s and beyond. Surpassing 20 EH/s in operational hashrate is more than double our hashrate from December,&#8221; said&nbsp;Zach Bradford, CEO of CleanSpark. 
&#8220;Doubling our hashrate takes grit and teamwork and our growth is a testament to the dedication of our teams. While our peers are exploring other avenues of income, we&#8217;re laser-focused on delivering results and increasing our&nbsp;bitcoin&nbsp;mining hashrate and associated revenues.&#8221;
CleanSpark also provided an update on its <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39529703/cleanspark-announces-griid-infrastructure-takeover-deal-digging-into-the-details">recent agreement</a> to acquire GRIID Infrastructure. CleanSpark said it closed its acquisition of five turnkey sites in&nbsp;Georgia, providing 60 MW of immediately available data center infrastructure. 
Once fully deployed, the company said it expects sites to add 3.7 EH/s of total hashrate. Approximately 1.7 EH/s have been deployed as of&nbsp;June 30, with additional hashrate expected to come online in July.
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39582074/bitcoin-miners-done-selling-63k-could-cause-miner-stocks-to-explode-higher-says-investor">Bitcoin Miners Done Selling, $63K Could Cause Miner Stocks To &#8216;Explode Higher,&#8217; Says Investor</a>
CLSK Price Action: <a href="https://www.benzinga.com/quote/CLSK">CleanSpark shares</a> were down 1.23% at $17.70 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Miloslav Hamřík from Pixabay.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

CLSK

What's Going On With Bitcoin Mining Stock CleanSpark Tuesday?

Shares of Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) were <a href="https://www.benzinga.com/quote/TEAM">climbing in early trading on Tuesday</a>.
Enterprise customers are likely to drive "the next wave of cloud migrations," triggering accelerated cloud growth, according to Piper Sandler.
The Analyst: Rob Owens upgraded the rating for Atlassian from Neutral to Overweight, while raising the price target from $200 to $225.
The Thesis: While currently only 30% of the company's cloud revenues are from enterprise customers, 82% of the remaining data center seats are enterprise, Owens said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"As these customers migrate to cloud, we think this will drive durable growth given the large uplifts seen for these customers, alongside more attractive NRR (net recurring revenue) dynamics," he added.
With new cloud products like Atlassian Intelligence and more improvements in the pipeline, "we believe enterprise migrations will pick up steam going forward," the analyst wrote.
Product innovation creates an enterprise cross-sell opportunity of more than $14 billion, which is so far underappreciated, he further stated.
TEAM Price Action: Shares of Atlassian had risen by 1.62% to $181.14 at the time of publication on Tuesday.
See Also: 
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39348581/janet-yellen-dismisses-donald-trumps-proposal-to-replace-income-tax-with-tariffs-the-impact-would-be" target="_blank" rel="noreferrer noopener">Janet Yellen Says Trump's Proposal To Replace Income Tax With Tariffs Would ‘Make Life Unaffordable …'</a></li>
</ul>

Analyst Color

Long Ideas

Upgrades

Price Target

Analyst Ratings

TEAM

Atlassian To Benefit From The 'Next Wave Of Cloud Growth', Says Bullish Analyst

JP Morgan analyst Jimmy Bhullar maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Overweight and raises the price target from $85 to $88.

VOYA

JP Morgan Maintains Overweight on Voya Financial, Raises Price Target to $88

Lamb Weston Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) short percent of float has risen 7.63% since its last report. The company recently reported that it has 8.24 million shares sold short, which is 6.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.28 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lamb Weston Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719933322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lamb Weston Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lamb Weston Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lamb Weston Hldgs's peer group average for short interest as a percentage of float is 4.34%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Lamb Weston Hldgs's Recent Short Interest

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 17.02% since its last report. The company recently reported that it has 20.64 million shares sold short, which is 1.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719933317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 10.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into CVS Health's Recent Short Interest

Texas Pacific Land's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) short percent of float has risen 8.06% since its last report. The company recently reported that it has 877 thousand shares sold short, which is 5.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Texas Pacific Land Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719933311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Texas Pacific Land has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Texas Pacific Land's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Texas Pacific Land's peer group average for short interest as a percentage of float is 6.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(TPL) - Analyzing Texas Pacific Land's Short Interest

JP Morgan analyst Jimmy Bhullar maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Overweight and raises the price target from $58 to $64.

JP Morgan Maintains Overweight on Unum Gr, Raises Price Target to $64

Evercore ISI Group analyst Michael Montani maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a In-Line and lowers the price target from $151 to $148.

Evercore ISI Group Maintains In-Line on Dollar Gen, Lowers Price Target to $148

Argus Research analyst Kristina Ruggeri reiterates Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Hold.

Reiteration

Argus Research Reiterates Hold on Ralph Lauren

Evercore ISI Group analyst Michael Montani maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a In-Line and raises the price target from $118 to $135.

CVNA

Evercore ISI Group Maintains In-Line on Carvana, Raises Price Target to $135

Federal Reserve

Fed's Goolsbee Says Sees Warning Signs From Real Economy; Using Europe's Housing Inflation Measures, We Would Be At 2% Already; Inflation Arc Clearly Downward; Continued Progress On Inflation Would Increase Confidence; Immigration's First-Order Impact Is On Population, Leading To Higher Steady-State Monthly Job Gains

Evercore ISI Group analyst Vijay Jayant maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Outperform and lowers the price target from $50 to $48.

CMCSA

Evercore ISI Group Maintains Outperform on Comcast, Lowers Price Target to $48

JP Morgan analyst Jimmy Bhullar maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Neutral and raises the price target from $195 to $208.

JP Morgan Maintains Neutral on Reinsurance Gr, Raises Price Target to $208

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $78 to $81.

Evercore ISI Group Maintains Outperform on Boston Scientific, Raises Price Target to $81

Fed's Goolsbee Still Thinks Soft Landing Is Possible; Only Wants To Stay Restrictive As Long As Necessary; Expects Inflation To Drop To 2%; Real Economy Weakening From Very "Hot" Level; Doesn't Believe Last Mile On Inflation Will Take Longer

Evercore ISI Group analyst Vijay Kumar maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a In-Line and raises the price target from $15 to $15.5.

BLCO

Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $15.5

Infobird Co. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) on Thursday announced it has entered into an equity acquisition agreement with Shangri-La Trading Limited.
The Details:
According to an SEC filing, Infobird will acquire 65% of the issued and outstanding equity of Pure Tech Global Limited. The acquisition is expected to be closed in July 2024.&nbsp;
The aggregate purchase price for the equity acquisition was approximately $40 million and will be funded using the cash on hand of $33 million and a promissory note of $7 million.
Read Next: <a href="https://www.benzinga.com/news/24/07/39585976/lawsuit-against-keith-gill-voluntarily-dismissed-whats-going-on-with-gamestop-stock">Lawsuit Against Keith Gill Voluntarily Dismissed: What&#8217;s Going On With GameStop Stock?</a>
Infobird shares are moving on heavy trading volume as investors digest the news. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 2.18 million shares have already been traded in the session and the stock has a float of only 1.338 million shares. It should also be noted that 15.13% available shares are being sold short which can add to price volatility when combined with heavy trading volume.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Infobird shares are trading below the stock&#8217;s 50-day moving average of $3.74 and near its 52-week low of $2.90.&nbsp;
<h2 class="wp-block-heading">How To Buy IFBD Stock:</h2>
By now you're likely curious about how to participate in the market for Infobird &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Infobird, which is trading at $2.96 as of publishing time, $100 would buy you 33.78 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
IFBD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Infobird shares are down 2.03% at $2.90 at the time of publication Tuesday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39581491/whats-going-on-with-cruise-stocks-as-category-4-hurricane-beryl-churns-in-the-caribbean">What&#8217;s Going On With Cruise Stocks As Category 4 Hurricane Beryl Churns In the Caribbean?</a></li>
</ul>
Image: Shutterstock

IFBD

Why Infobird Stock Is Gliding Higher

JP Morgan analyst Jimmy Bhullar maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Neutral and raises the price target from $118 to $128.

JP Morgan Maintains Neutral on Prudential Financial, Raises Price Target to $128

Fed's Goolsbee Says As Inflation Comes Down, Policy Gets Tighter; Thinks We Should Tighten By Choice, Not Default

On Tuesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating Carvykti (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for relapsed or lenalidomide-refractory multiple myeloma <a href="https://www.benzinga.com/pressreleases/24/07/n39592648/carvykti-ciltacabtagene-autoleucel-achieved-statistically-significant-and-clinically-meaningful-im" target="_blank" rel="noreferrer noopener">after one prior line of therapy</a>.
In simple words, the study compared Carvykti, a treatment for multiple myeloma, to other standard therapies. This research focused on patients whose multiple myeloma has returned or did not respond to initial treatments, after only one previous treatment.
The interim analysis showed a statistically significant and clinically meaningful improvement in overall survival for patients treated with Carvykti&nbsp;compared to standard therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39419157/johnson-johnson-faces-new-lawsuit-s-related-to-its-talc-products" rel="noreferrer noopener">Johnson &amp; Johnson Faces New Lawsuit(s) Related To Its Talc Products</a>.
Safety data were consistent with the approved label.
&#8220;Carvykti, a one-time infusion, is now the&nbsp;first cell therapy to significantly improve overall survival versus standard of care for patients with myeloma as early as second line,&#8221; said&nbsp;Jordan Schecter, Vice President, Disease Area Leader, Multiple Myeloma, Johnson &amp; Johnson Innovative Medicine.
Carvykti received FDA approval in&nbsp;February 2022&nbsp;for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
In&nbsp;April 2024, Carvykti&nbsp;was&nbsp;approved in the U.S. for&nbsp;adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
In&nbsp;April 2024, the European Medicines Agency approved a Type II variation for Carvykti for adults with relapsed and refractory multiple myeloma who have received at least one prior therapy.
Carvykti&nbsp;is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient&#8217;s T-cells with a transgene encoding chimeric antigen receptor that directs the CAR-positive T cells to eliminate cells that express BCMA.
In&nbsp;December 2017, Janssen Biotech Inc, a Johnson &amp; Johnson company, entered into an exclusive worldwide license and collaboration agreement with Legend Biotech&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) to develop and commercialize Carvykti.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/06/39418047/johnson-johnsons-arthritis-drug-shows-potential-in-crohns-disease" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Arthritis Drug Shows Potential In Crohn&#8217;s Disease</a></li>
</ul>
Price Action: JNJ shares are down 0.12% at $146.27 at the last check on Tuesday.
Image By Sundry Photography Via Shutterstock

Biotech

Large Cap

Health Care

General

LEGN

Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients

Financing

Press Releases

Thesis Gold Announces $13 Million Private Placement Financing

Thesis Gold Receives Positive Metallurgical Tests Results for Lawyers-Ranch Project: Achieves Average Precious Metal Recovery of 95% for Gold and 92% for Silver

Thesis Gold Announces $20 Million Private Placement

TSXV:TAU

Thesis Gold

Source: <a href="https://www.streetwisereports.com/article/2024/05/10/analyst-says-gold-co-offering-superior-returns-on-the-path-to-production.html?utm_medium=feed">Ron Stewart 05/10/2024</a>

Thesis Gold Inc. is focused on advancing the exploration, engineering, and metallurgical test work on the combined project to create a new, intermediate gold producer, according to a Leede Jones Gable research note.

Leede Jones Gable analyst Ron Stewart initiated coverage on Thesis Gold Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/THSGF#OTC">THSGF</a>) with a Buy rating and a February 2025 price target of CA$2.30 per share, according to a research report published on May 9, 2024. The analyst believes that Thesis offers investors the opportunity for superior returns over the next few years as the company advances on the path to production.

&quot;Thesis was formed through a business combination that brought together the multi-million-ounce Lawyers project and contiguous Ranch exploration project in north central BC&quot; Stewart noted. &quot;The company is focused on advancing the exploration, engineering, and metallurgical test work on the combined project to create a new, intermediate gold producer.&quot;

The current NI 43-101 mineral resource for Thesis Gold stands at 5.0 million gold-equivalent ounces (GEO), comprised of 4.0 million oz GEO of measured and indicated resources (82.0Mt at 1.11 grams per tonne gold (g/t Au), 31.9 g/t Ag) and 727K oz GEO of Inferred resources (12.4Mt at 1.48 g/t Au, 24.8 g/t Ag).

&quot;Despite the significant resource already identified, we believe the 325km2 property offers excellent exploration potential for additional high-quality resources&quot; Stewart commented.

The analyst highlighted that over 20 prospects and deposits on the Ranch property remain open for exploration and resource expansion, with high-grade mineralization open at depth beneath the AGB and Cliff deposits at Lawyers.

Thesis Gold is planning to incorporate underground mining at Lawyers and satellite feed from Ranch in an updated Preliminary Economic Assessment (PEA), expected by late summer.

&quot;We expect a significant increase in the annual GEO production to average over 200K oz per year over a mine life of 10 to 15 years&quot; Stewart stated.

The analyst pointed out that Thesis Gold is currently trading at a 65% discount to peers on an enterprise value to total resource ounce basis, with an estimated valuation of approximately US$20/oz, compared to a peer average of US$54.9/oz.

Stewart also highlighted the appointment of William (Bill) Lytle as Chairman in February, noting that &quot;Mr. Lytle is a mining engineer with extensive construction and operating experience and is currently the Vice President &amp; COO of B2Gold Corp (BTO.T, Not Rated), a highly successful intermediate international gold producer.&quot;

Leede Jones Gable&#39;s valuation of Thesis Gold is based on an adjusted Net Asset Value (NAV) per share, comprised of the estimated fully financed, after-tax discounted cash flow (DCF) plus the additional exploration value from the residual contained metal not included in the mine plan.

&quot;Our estimated NAV at 5% includes a DCF of CA$871M and exploration value of CA$98M. We adjust the DCF by 50% to reflect the exploration stage of the project to arrive at an adjusted NAV of CA$436M, resulting in a target price of CA$2.30/share&quot; Stewart explained.

The analyst identified several key catalysts for Thesis Gold, including additional metallurgical test results expected in the current quarter, an updated PEA by the end of the summer, and the announcement of the 2024 exploration program by the end of the quarter.

With a Buy rating and a target price of CA$2.30 per share, representing a potential return of 199% from the current price of CA$0.77, Leede Jones Gable sees significant upside potential for investors in Thesis Gold as the company advances its projects toward production.

Important Disclosures:

<ol>
	<li>This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports&#39; terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.</li>
</ol>

Disclosures for Leede Jones Gable, Thesis Gold Inc., May 9, 2024

Important Information and Legal Disclaimers Leede Jones Gable Inc. (LJG) is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of LJG. LJG cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value and you may lose money. LJG employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of IIROC

Description of Disclosure Codes 1. LJG and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company&#39;s securities directly or through derivatives. 3. LJG or a director or officer of LJG or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. LJG provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. LJG expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon LJG investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. LJG acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst.

Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Jones Gable Inc. (LJG) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the LJG website and are accessible to customers who are entitled the firm&#39;s research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Jones Gable Inc. (LJG) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon LJG investment banking revenue.

Canadian Disclosures This research has been approved by Leede Jones Gable Inc. (LJG), which accepts sole responsibility for this research and its dissemination in Canada. LJG is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a LJG Registered Representative.

U.S. Disclosures This research report was prepared by Leede Jones Gable Inc. (LJG), a member of the Investment Industry Regulatory Organization of Canada (IIROC) and the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. LJG is not registered as a broker-dealer in the United States and is not be subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Thesis Gold

News

Latest news for Thesis Gold (OTC:THSGF) Stock

Monday, May 13, 2024